{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:18:21Z","timestamp":1781104701759,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"DOI":"10.7759\/cureus.42785","type":"journal-article","created":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T09:34:42Z","timestamp":1690882482000},"source":"Crossref","is-referenced-by-count":2,"title":["The Role of Non-genetic Therapies to Reduce the Incidence of Sickle Cell Crisis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Shravya","family":"Pingili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaya Krishna","family":"Makkena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo  P","family":"Jaramillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babatope L","family":"Awosusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javaria","family":"Ayyub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan Nareshbhai","family":"Dabhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namra V","family":"Gohil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"Tanveer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pousette","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genom-083117-021320","article-title":"Sickle cell anemia and its phenotypes","volume":"19","author":"Williams TN","year":"2018","unstructured":"Williams TN, Thein SL. Sickle cell anemia and its phenotypes. Annu Rev Genomics Hum Genet. 2018, 19:113-47. 10.1146\/annurev-genom-083117-021320","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"ref2","article-title":"Sickle cell trait","author":"Ashorobi D","unstructured":"Ashorobi D, Ramsey A, Yarrarapu SN, Bhatt R. Sickle cell trait. 2022 (ed): StatPearls, Treasure Island (FL);"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-1092-5","article-title":"Sickle cell vaso-occlusive crisis: it's a gut feeling","volume":"14","author":"Lim SH","year":"2016","unstructured":"Lim SH, Fast L, Morris A. Sickle cell vaso-occlusive crisis: it's a gut feeling. J Transl Med. 2016, 14:334. 10.1186\/s12967-016-1092-5","journal-title":"J Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.emc.2018.04.002","article-title":"Rapid fire: sickle cell disease","volume":"36","author":"Porter M","year":"2018","unstructured":"Porter M. Rapid fire: sickle cell disease. Emerg Med Clin North Am. 2018, 36:567-76. 10.1016\/j.emc.2018.04.002","journal-title":"Emerg Med Clin North Am"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511544835.056","article-title":"Sickle Cell Crisis","author":"Bradshaw H","year":"2008","unstructured":"Bradshaw H, Woolridge D. Sickle Cell Crisis. Emergency Department Analgesia: An Evidence-Based Guide . Thomas SH (ed): Cambridge University Press, Cambridge; 2008. 365-79. 10.1017\/CBO9780511544835.056"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021, 372:n160. 10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13896","article-title":"Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease","volume":"85","author":"Hutchaleelaha A","year":"2019","unstructured":"Hutchaleelaha A, Patel M, Washington C, et al.. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease. Br J Clin Pharmacol. 2019, 85:1290-302. 10.1111\/bcp.13896","journal-title":"Br J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25308","article-title":"Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis","volume":"94","author":"Kutlar A","year":"2019","unstructured":"Kutlar A, Kanter J, Liles DK, et al.. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. Am J Hematol. 2019, 94:55-61. 10.1002\/ajh.25308","journal-title":"Am J Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara Y","year":"2018","unstructured":"Niihara Y, Miller ST, Kanter J, et al.. A phase 3 trial of l-glutamine in sickle cell disease. N Engl J Med. 2018, 379:226-35. 10.1056\/NEJMoa1715971","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011358.pub3","article-title":"Magnesium for treating sickle cell disease","volume":"9","author":"Than NN","year":"2019","unstructured":"Than NN, Soe HH, Palaniappan SK, Abas AB, De Franceschi L. Magnesium for treating sickle cell disease. Cochrane Database Syst Rev. 2019, 9:CD011358. 10.1002\/14651858.CD011358.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012082.pub2","article-title":"Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews","volume":"8","author":"Fortin PM","year":"2018","unstructured":"Fortin PM, Hopewell S, Estcourt LJ. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2018, 8:CD012082. 10.1002\/14651858.CD012082.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003426.pub6","article-title":"Drugs for preventing red blood cell dehydration in people with sickle cell disease","volume":"10","author":"Nagalla S","year":"2018","unstructured":"Nagalla S, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst Rev. 2018, 10:CD003426. 10.1002\/14651858.CD003426.pub6","journal-title":"Cochrane Database Syst Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004448.pub7","article-title":"Phytomedicines (medicines derived from plants) for sickle cell disease","volume":"9","author":"Oniyangi O","year":"2020","unstructured":"Oniyangi O, Cohall DH. Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database Syst Rev. 2020, 9:CD004448. 10.1002\/14651858.CD004448.pub7","journal-title":"Cochrane Database Syst Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2020.08.008","article-title":"Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials","volume":"92","author":"Ali MA","year":"2020","unstructured":"Ali MA, Ahmad A, Chaudry H, Aiman W, Aamir S, Anwar MY, Khan A. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp Hematol. 2020, 92:11-18.e1. 10.1016\/j.exphem.2020.08.008","journal-title":"Exp Hematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01878","article-title":"E-selectin ligands in the human mononuclear phagocyte system: implications for infection, inflammation, and immunotherapy","volume":"8","author":"Silva M","year":"2017","unstructured":"Silva M, Videira PA, Sackstein R. E-selectin ligands in the human mononuclear phagocyte system: implications for infection, inflammation, and immunotherapy. Front Immunol. 2017, 8:1878. 10.3389\/fimmu.2017.01878","journal-title":"Front Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/1076029609352661","article-title":"Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion","volume":"16","author":"Mousa SA","year":"2010","unstructured":"Mousa SA, Al Momen A, Al Sayegh F, et al.. Management of painful vaso-occlusive crisis of sickle-cell anemia: consensus opinion. Clin Appl Thromb Hemost. 2010, 16:365-76. 10.1177\/1076029609352661","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3109\/03630269509005824","article-title":"The sickle cell painful crisis in adults: phases and objective signs","volume":"19","author":"Ballas SK","year":"1995","unstructured":"Ballas SK. The sickle cell painful crisis in adults: phases and objective signs. Hemoglobin. 1995, 19:323-33. 10.3109\/03630269509005824","journal-title":"Hemoglobin"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2004.07.006","article-title":"Are there phases to the vaso-occlusive painful episode in sickle cell disease?","volume":"29","author":"Jacob E","year":"2005","unstructured":"Jacob E, Beyer JE, Miaskowski C, Savedra M, Treadwell M, Styles L. Are there phases to the vaso-occlusive painful episode in sickle cell disease?. J Pain Symptom Manage. 2005, 29:392-400. 10.1016\/j.jpainsymman.2004.07.006","journal-title":"J Pain Symptom Manage"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.6b00491","article-title":"Discovery of GBT440, an orally bioavailable R-state stabilizer of sickle cell hemoglobin","volume":"8","author":"Metcalf B","year":"2017","unstructured":"Metcalf B, Chuang C, Dufu K, et al.. Discovery of GBT440, an orally bioavailable R-state stabilizer of sickle cell hemoglobin. ACS Med Chem Lett. 2017, 8:321-6. 10.1021\/acsmedchemlett.6b00491","journal-title":"ACS Med Chem Lett"},{"key":"ref21","unstructured":"Adakveo (crizanlizumab\u2010tmca) injection, for intravenous use. (2019). Accessed. May 28,2023: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761128s000lbl.pdf."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.2000.278.3.R628","article-title":"Mg(2+)-induced endothelium-dependent relaxation of blood vessels and blood pressure lowering: role of NO","volume":"278","author":"Yang ZW","year":"2000","unstructured":"Yang ZW, Gebrewold A, Nowakowski M, Altura BT, Altura BM. Mg(2+)-induced endothelium-dependent relaxation of blood vessels and blood pressure lowering: role of NO. Am J Physiol Regul Integr Comp Physiol. 2000, 278:R628-39. 10.1152\/ajpregu.2000.278.3.R628","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.ph.53.030191.001503","article-title":"Modulation of cardiac ion channels by magnesium","volume":"53","author":"Agus ZS","year":"1991","unstructured":"Agus ZS, Morad M. Modulation of cardiac ion channels by magnesium. Annu Rev Physiol. 1991, 53:299-307. 10.1146\/annurev.ph.53.030191.001503","journal-title":"Annu Rev Physiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.5.1451","article-title":"Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease","volume":"97","author":"Bennekou P","year":"2001","unstructured":"Bennekou P, de Franceschi L, Pedersen O, et al.. Treatment with NS3623, a novel Cl-conductance blocker, ameliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease. Blood. 2001, 97:1451-7. 10.1182\/blood.v97.5.1451","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-199502020-00005","article-title":"Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease","volume":"2","author":"Brugnara C","year":"1995","unstructured":"Brugnara C. Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease. Curr Opin Hematol. 1995, 2:132-8. 10.1097\/00062752-199502020-00005","journal-title":"Curr Opin Hematol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08520.x","article-title":"Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)","volume":"153","author":"Ataga KI","year":"2011","unstructured":"Ataga KI, Reid M, Ballas SK, et al.. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Br J Haematol. 2011, 153:92-104. 10.1111\/j.1365-2141.2010.08520.x","journal-title":"Br J Haematol"},{"key":"ref27","article-title":"Pharmacological profile of NIPRD 94\/002\/1-0: a novel herbal antisickling agent","volume":"3","author":"Gamaniel K","year":"1998","unstructured":"Gamaniel K, Amos S, Akah PA, Samuel BB, Kapu S, Olusola A. Pharmacological profile of NIPRD 94\/002\/1-0: a novel herbal antisickling agent. J Pharm Res Dev. 1998, 3:89-94.","journal-title":"J Pharm Res Dev"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/170871-the-role-of-non-genetic-therapies-to-reduce-the-incidence-of-sickle-cell-crisis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:45Z","timestamp":1707509025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/170871-the-role-of-non-genetic-therapies-to-reduce-the-incidence-of-sickle-cell-crisis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.42785","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}